Crystal form alpha of compound A-benzoate (1:1), preparation method thereof, and pharmaceutical composition containing crystal form alpha

The invention belongs to the field of chemical medicine preparation, and more specifically relates to a crystal form alpha of dipeptidyl peptidase-IV inhibitor compound A-benzoate (1:1), a preparation method thereof, and a pharmaceutical composition containing the crystal form alpha.